First Trust NYSE Arca Biotechnology Index Fund
236 hedge funds and large institutions have $860M invested in First Trust NYSE Arca Biotechnology Index Fund in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 79 reducing their positions, and 22 closing their positions.
27% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 22
1% more funds holding
Funds holding: 233 → 236 (+3)
1.02% more ownership
Funds ownership: 46.07% → 47.09% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $908M → $860M (-$47.4M)
11% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Karp Capital Management
Sausalito,
California
|
+$11.1M |
| 2 |
AIC
Ameritas Investment Company
Lincoln,
Nebraska
|
+$6.63M |
| 3 |
QAM
Q3 Asset Management
Birmingham,
Michigan
|
+$5.96M |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$3.61M |
| 5 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$19.2M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$7.19M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$5.16M |
| 4 |
LPL Financial
San Diego,
California
|
-$4.41M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$3.31M |
FBT Hedge Fund Activity: Q3 2021 in Review
236 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q3 2021, worth a combined $860M — down 5.2% from $908M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FBT positions and 22 closed out — a net gain of 6 holders — while 70 added to existing stakes and 79 trimmed.
The largest buyer was Karp Capital Management, opening a new position worth an estimated $11.1M. The largest seller was Morgan Stanley, cutting an estimated $19.2M.
- 236 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q3 2021, up from 233 in Q2 2021.
- Funds reported $860M of First Trust NYSE Arca Biotechnology Index Fund stock for Q3 2021, down 5.2% quarter-over-quarter.
- 28 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q3 2021 and 22 closed out, a net change of +6 holders.
- The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q3 2021 was Karp Capital Management, an estimated $11.1M added.
- The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q3 2021 was Morgan Stanley, an estimated $19.2M sold.
Based on aggregated 13F filings for Q3 2021.